Targeting transcription factors for cancer therapy

Current Pharmaceutical Design

Volumn 11, Issue 22, 2005, Pages 2873-2887

  Redell, Michele S ^a   Tweardy, David J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PEPTIDE DERIVATIVE; PLASMID DNA; REGULATOR PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STEROID; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CARCINOGENESIS; CARCINOMA; DNA BINDING; DOWN REGULATION; DRUG TARGETING; GENE MUTATION; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LEUKEMIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RETICULOSARCOMA; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA-BINDING PROTEINS; DRUG DESIGN; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MILK PROTEINS; NF-KAPPA B; NUCLEAR PROTEINS; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 22944434871     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054546699     Document Type: Review

References (165)

1. van Dam H, Castellazzi M. Distinct roles of Jun:Fos and Jun:ATF dimers in oncogenesis. Oncogene 2001; 20: 243-64.
2. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4: E131-E6.
3. Weston K. Reassessing the role of C-MYB in tumorigenesis. Oncogene 1999; 18: 3034-8.
4. Cho-Chung YS, Park YG, Nesterova M, Lee YN, Cho YS. CRE-decoy oligonucleotide-inhibition of gene expression and tumor growth. Mol Cell Biochem 2000; 212: 29-34.
5. Young MR, Yang HS, Colburn NH. Promising molecular targets for cancer prevention: AP-I, NF-kappa B and Pdcd4. Trends Mol Med 2003; 9: 36-41.
6. Hermeking H. The MYC oncogene as a cancer drug target. Curr Cancer Drug Targets 2003; 3: 163-75.
7. Lu X, Pearson A, Lunec J. The MYCN oncoprotein as a drug development target. Cancer Lett 2003; 197: 125-30.
8. Gewirtz AM. Myb targeted therapeutics for the treatment of human malignancies. Oncogene 1999; 18: 3056-62.
9. Ramsay RG, Barton AL, Gonda TJ. Targeting c-Myb expression in human disease. Expert Opin Ther Targets 2003; 7: 235-48.
10. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1: 181-93.
11. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002; 41: 41-55.
12. Crowe DL. Receptor selective synthetic retinoids as potential cancer chemotherapy agents. Curr Cancer Drug Targets 2002; 2: 77-86.
13. Rabbitts TH, Appert A, Chung G, Collins EC, Drynan L, Forster A, et al. Mouse models of human chromosomal translocations and approaches to cancer therapy. Blood Cells Mol Dis 2001; 27: 249-59.
14. Rodriguez-Garcia A, Sanchez-Martin M, Perez-Losada J, Perez-Mancera PA, Sagrera-Aparisi A, Gutierrez-Cianca N, et al. Selective destruction of tumor cells through specific inhibition of products resulting from chromosomal translocations. Curr Cancer Drug Targets 2001; 1: 109-19.
15. Wen Z, Zhong Z, Darnell JE, Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995; 82: 241-50.
16. Zhang X, Blenis J, Li HC, Schindler C, Chen-Kiang S. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science 1995; 267: 1990-4.
17. Akira S. Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells 1999; 17: 138-46.
18. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996; 84: 443-50.
19. Meraz MA, White JM, Sheehan KCF, Bach EA, Rodig SJ, Dighe AS, et al. Targeted disruption of Stat1 gene in mice reveals unexpected physiologic specificity in the JAK STAT signaling pathway. Cell 1996; 84: 431-42.
20. Kaplan MH, Sun Y-L, Hoey T, Grusby MJ. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 1996; 382: 174-7.
21. Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 1996; 382: 171-4.
22. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 1999; 283: 987-90.
23. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformational change. Science 1999; 283: 990-3.
24. Schaefer TS, Sanders LK, Nathans D. Cooperative transcriptional activity of Jun and Stat3β, a short form of Stat3. Proc Natl Acad Sci USA 1995; 92: 9097-101.
25. Chakraborty A, White SM, Schaefer TS, Ball ED, Dyer KF, Tweardy DJ. Granulocyte colony-stimulating factor activation of Stat3α and Stat3β in immature normal and leukemic human myeloid cells. Blood 1996; 88: 2442-9.
26. Caldenhoven E, van Dijk TB, Solari R, Armstrong J, Raaijmakers JAM, Lammers J-WJ, et al. STAT3β, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J Biol Chem 1996; 271: 13221-7.
27. Shao H, Quintero AJ, Tweardy DJ. Identification and characterization of cis elements in the STAT3 gene regulating STAT3α and STAT3β messenger RNA splicing. Blood 2001; 98: 3853-6.
28. Biethan S, Alves F, Wilde S, Hiddemann W, Spiekermann K. Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. Exp Hematol 1999; 27: 885-94.
29. Chakraborty A, Tweardy DJ. Granulocyte colony-stimulating factor activates a 72-kDa isoform of STAT3 in human neutrophils. J Leukoc Biol 1998; 64: 675-80.
30. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999; 98: 295-303.
31. Fukada T, Hibi M, Yamanaka Y, Takahashi-Tezuka M, Fujitani Y, Yamaguchi T, et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 1996; 5: 449-60.
32. Kip1. Oncogene 2000; 19: 3290-8.
33. O'Farrell AM, Parry DA, Zindy F, Roussel ME, Lees E, Moore KW, et al. Stat3-dependent induction of p19INK4D by IL-10 contributes to inhibition of macrophage proliferation. J Immunol 2000; 164: 4607-15.
34. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 2001; 98: 7319-24.
35. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-15.
36. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001; 107: 351-62.
37. Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T. Synergistic roles for Pim-I and c-Myc in STAT3-mediated cell cycle progression and anti-apoptosis. Immunity 1999; 11: 709-19.
38. Brender C, Nielsen M, Mikkelsen G, Zhang Q, Wasik M, Billestrup N, et al. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood 2001; 97: 1056-62.
39. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21: 2000-8.
40. Yu C-L, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995; 269: 81-3.
41. Garcia R, Yu C-L, Hudnall A, Catlett R, Nelson KL, Smithgall T, et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 1997; 8: 1267-76.
42. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE, Jr. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998; 18: 2553-8.
43. Turkson J, Bowman T, Garcia R, Caldenhoven E, de Groot RP, Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1998; 18: 2545-52.
44. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19: 2474-88.
45. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8: 945-54.
46. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000; 19: 2496-504.
47. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000; 19: 6613-26.
48. Schuringa J-j, Wierenga ATJ, Kruijer W, Vellenga E. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 2000; 95: 3765-70.
49. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-84.
50. Grandis JR, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996; 78: 1284-92.
51. Grandis JR, Chakraborty A, Melhem MF, Zeng Q, Tweardy DJ. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene 1997; 15: 409-16.
52. Grandis JR, Chakraborty A, Zeng Q, Melhem ME, Tweardy DJ. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem 1998; 69: 55-62.
53. Grandis JR, Zeng Q, Drenning SD. Epidermal growth factor receptor-mediated Stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope 2000; 110: 868-74.
54. Li L, Shaw PE. Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines. J Biol Chem 2002; 277: 17397-405.
55. Yoshikawa H, Matsubara K, Qian G-S, Jackson P, Groopman JD, Manning JE, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001; 28: 29-35.
56. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002; 62: 6659-66.
57. Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR, et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 2002; 99: 252-7.
58. Becker S, Groner B, Muller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 1998; 94: 145-51.
59. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo s, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000; 97: 4227-32.
60. Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 2001; 276: 45443-55.
61. Ren Z, Cabell LA, Schaefer TS, McMurray JS. Identification of a high-affinity phosphopeptide inhibitor of Stat3. Bioorg Med Chem Lett 2003; 13: 633-6.
62. Shao H, Cheng HY, Cook RG, Tweardy DJ. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 2003; 63: 3923-30.
63. Wiederkehr-Adam M, Ernst P, Muller K, Bieck E, Gombert FO, Ottl J, et al. Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3. J Biol Chem 2003; 278: 16117-28.
64. Shao H, Xu X, Mastrangelo MA, Jing N, Cook RG, Legge GD, et al. Structural requirements for signal transduction and activator of transcription 3 binding to phosphotyrosine ligands containing the YXXQ motif. J Biol Chem 2004; In Press.
65. Xia L, Wang L, Chung AS, Ivanov SS, Ling MY, Dragoi AM, et al. Identification of both positive and negative domains within EGF receptor COOH-terminal region for STAT activation. J Biol Chem 2002; 277: 30716-23.
66. Jing N, Li Y, Xu X, Sha W, Li P, Feng L et al. Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells. DNA Cell Biol 2003; 22: 685-696.
67. Jing N, Li Y, Xiong W, Jing L, Tweardy DJ. G-quartet oligonucleotides: a new class of Stat3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res 2004; 64: 6603-6609.
68. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 1997; 11: 179-86.
69. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci USA 1997; 94: 7239-44.
70. Matsumura I, Kitamura T, Wakao H, Tanaka H, Hashimoto K, Albanese C, et al. Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J 1999; 118: 1367-77.
71. Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui AL-F, Kitamura T. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J 1999; 18: 4754-65.
72. Lacronique V, Boureux A, Monni R, Dumon S, Mauchauffe M, Mayeux P, et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 2000; 95: 2076-83.
73. Friedrichsen BN, Richter HE, Hansen JA, Rhodes CJ, Nielsen JH, Billestrup N, et al. Signal transducer and activator of transcription 5 activation is sufficient to drive transcriptional induction of cyclin D2 gene and proliferation of rat pancreatic beta-cells. Mol Endocrinol 2003; 17: 945-58.
74. Azam M, Lee C. Strehlow I, Schindler C. Functionally distinct isoforms of STAT5 are generated by protein processing. Immunity 1997; 6: 691-701.
75. Kazansky AV, Raught B, Lindsey SM, Wang YF, Rosen JM. Regulation of mammary gland factor/Stat5a during mammary gland development. Mol Endocrinol 1995; 9: 1598-609.
76. Ripperger JA, Fritz S, Richter K, Hocke GM, Lottspeich F, Fey GH. Transcription factors Stat3 and Stat5b are present in rat liver nuclei late in an acute phase response and bind interleukin-6 response elements. J Biol Chem 1995; 270: 29998-30006.
77. de Groot RP, Raaijmakers JAM, Lammers J-WJ, Jove R, Koenderman L. STAT5 activation by BCR-ABL contributes to transformation of K562 leukemia cells. Blood 1999; 94: 1108-12.
78. Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 1997; 159: 4720-8.
79. Shuai K, Hallpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of Stat5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996; 13: 247-54.
80. Spiekermann K, Pau M, Schwab R, Schmieja K, Franzrahe S, Hiddemann W. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol 2002; 30: 262-71.
81. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia Leukemia 1996; 10: 1911-8.
82. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000; 19: 624-31.
83. Birkenkamp KU, Geugien M, Lemmink HH, Kruijer W, Vellenga E. Regulation of constitutive Stat5 phosphorylation in acute myeloid leukemia blasts. Leukemia 2001; 15: 1923-31.
84. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000; 96: 3907-14.
85. Onishi M, Nosaka T, Misawa K, Mui AL-F, Gorman D, McMahon M, et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol 1998; 18: 3871-9.
86. Schwaller J, Parganas E, Wang D, Cain D, Aster JC, Williams IR, et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell 2000; 6: 693-704.
87. Xi S, Zhang Q, Gooding WE, Smithgall TE, Grandis JR. Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res 2003; 63: 6763-71.
88. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed. cells. Blood 2000; 95: 2118-25.
89. Singh H, Sen R, Baltimore D, Sharp PA. A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes. Nature 1986; 319: 154-8.
90. Nakshatri H, Goulet RJ, Jr. NF-κB and breast cancer. Curr Probl Cancer 2002; 26: 277-310.
91. Ruland J, Mak TW. Transducing signals from antigen receptors to nuclear factor κB. Immunol Rev 2003; 193: 93-100.
92. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappaB. Nature 1995; 376: 167-70.
93. Rayet B, Gelinas C. Aberrant rel/rfkb genes and activity in human cancer. Oncogene 1999; 18.
94. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000; 14: 399-402.
95. Dokter WH, Tuyt L, Sierdsema SJ, Esseling MT, Vellenga E. The spontaneous expression of interleukin-1 beta and interleukin-6 is associated with spontaneous expression of AP-1 and NF-kappaB transcription factor in acute myeloblastic leukemia cells. Leukemia 1995; 9: 425-32.
96. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-7.
97. Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K, et al. High-level nuclear NF-κB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996; 87: 4340-7.
98. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheideref C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999; 18: 943-53.
99. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IκBα gene in Hodgkin's disease suggest a tumor suppressor role for IkappaBalpha. Oncogene 1999; 18: 3063-70.
100. Wood KM, Roff M, Hay RT. Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB. Oncogene 1998; 16: 2131-9.
101. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997; 17: 3629-39.
102. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclcar factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5: 119-27.
103. Oya M, Ohtsubo M, Takayanagi A, Tachibana ME, Shimuzi N, Murai M. Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in reveal cancer cells. Oncogene 2001; 20: 3888-96.
104. Poulaki V, Mitsiades CS, Joussen AM, Lappas A, Kirchhof B, Mitsiades N. Constitutive nuclear factor-κB activity is crucial for human retinoblastoma cell viability. Am J Pathol 2002; 161: 2229-40.
105. Shattuck-Brandt RL, Richmond A. Enhanced degradation of I-KappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells. Cancer Res 1997; 57: 3032-9.
106. Beauparlant P, Kwan I, Bitar R, Chou P, Koromilas AE, Sonenberg N, et al. Disruption of I kappa B alpha regulation by antisense RNA expression leads to malignant transformation. Oncogene 1994; 9: 3189-97.
107. Epinat J-C, Gilmore TD. Diverse agents act at multiple levels to inhibit the Rel/NF-κB signal transduction pathway. Oncogene 1999; 18: 6896-909.
108. Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, et al. Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci USA 1993; 90: 9901-5.
109. Kawamura I, Morishita R, Tomita N, Lacey E, Aketa M, Tsujimoto S, et al. Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model. Gene Ther 1999; 6: 91-7.
110. Kawamura I, Morishita R, Tsujimoto S, Manda T, Tomoi M, Tomita N, et al. Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Ther 2001; 8: 905-12.
111. Galien R, Garcia T. Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-κB site. Nucleic Acids Res 1997; 25: 2424-9.
112. Stein B, Yang MN. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappaB and C/EBP beta. Mol Cell Biol 1995; 15: 4971-9.
113. McKay LI, Cidlowski JA. Cross-talk between nuclear factor-κB and the steroid hormone receptors: mechanisms of mutual antagonism. Mol Endocrinol 1998; 12: 45-56.
114. Ray A, Prefontaine K. Physical association and functional antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994; 91: 752-6.
115. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocaiion of transcription factor NF-kappaB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995; 270: 14255-8.
116. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Biologic sequelae of nuclear factor-κB blockade an multiple myeloma: therapeutic applications. Blood 2002; 99: 4079-86.
117. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100: 2961-9.
118. Wang C-Y, Cusack JC, Jr., Liu R, Baldwin AS, Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999; 5: 412-7.
119. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteosome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-6.
120. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639-47.
121. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS, Jr. Inhibition of NF-kappaB activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001; 276: 22382-7.
122. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: A treasure trove for drug development. Nat Rev Drug Disc 2004; 3: 17-26.
123. Ohh M, Park CW, Ivan V, Hoffman MA, Kim TY, Huang LE, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000; 2: 423-7.
124. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993; 90: 4304-8.
125. Semenza GL. Signal transduction to hypoxia-indueible factor 1. Biochem Pharmacol 2002; 64: 993-8.
126. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu M-M, et al. Modulation of hypoxia-inducible factor 1α expression by the epidermis growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 1541-5.
127. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-indueible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 2995-4004.
128. Sodhi A, Mortaner S, Patel V, Zohar M, Bais C, Mesri EA, et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1α. Cancer Res 2000; 60: 4873-80.
129. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J. p42/p44 Mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999; 274: 32631-7.
130. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphotidylinositoi 3-kinase signaling in colon cancer cells. J Biol Chem 2002; 277: 38205-11.
131. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor Iα in vascular smooth muscle cells. J Biol Chem 2000; 275: 26765-71.
132. Jiang B-H, Agani F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997; 57: 5328-35.
133. Mazure NM, Chen EY, Yeh P, Ladercute KR, Giaccia AJ. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 1996; 56: 3436-40.
134. Chan DA, Sutphin PD, Denko NC, Giaccia AJ. Role of prolyl hydroxylation in oncogenically stabilized hypoxia inducible factor-1α. J Biol Chem 2002; 277: 40112-7.
135. Jiang B-H, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001; 12: 363-9.
136. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 2000; 14: 34-44.
137. Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 2002; 277: 23111-5.
138. Feldser D, Agani F, Iyer NV, Pak B, Perreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res 1999; 59: 3915-8.
139. Gunaratnam L, Morley M, Franovic A, de Paulsen N, Mekhail K, Parolin DAE, et al. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in (VHL-/-) renal cell carcinoma cells. J Biol Chem 2003; 278: 44966-74.
140. Caniggia I, Mostachfi H, Winter J, Gassmann M, Lye SJ, Kuliszewski M, et al. Hypoxia-inducible factor-I mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J Clin Invest 2000; 105: 577-87.
141. Berger AP, Kofler K, Bektic J, Rogatsch H, Steiner H, Bartsch G, et al. Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 2003; 57: 57-65.
142. de Paulsen N, Brychzy A, Fournier MC, Klausner RD, Gnarra JR, Pause et al.. Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 2001; 98: 1387-92.
143. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5.
144. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411-21.
145. Wiesener MS, Munchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001; 61: 5215-22.
146. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Upregulation of Hypoxia-inducible factors HIF-Ialpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 2000; 19: 5435-43.
147. Bos R, Zhong H, Hanrahan CF, Mommers ECM, Semenza GL, Pinedo HM, et al. Levels of hypoxia-inducible factor 1-alpha during breast carcinogenesis. J Natl Cancer Inst 2001; 93: 309-14.
148. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Ciin Cancer Res 2002; 8: 1831-7.
149. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. Expression of hypoxia-inducible factor 1α in brain tumors. Cancer 2000; 88: 2606-18.
150. Birner P, Gatterbauer B, Oberhuber G, Schindl M, Rossler K, Prodinger A, et al. Expression of hypoxia-inducible factor-1alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 2001; 92: 165-71.
151. Birner P, Schind M, Obermair A, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000; 60: 4693-6.
152. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61: 2911-6.
153. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, et al. Constitutive expression of hypoxia-inducible factor-1α renders pancreatic cancer cells resistant to all induced by hypoxia and nutrient deprivation. Cancer Res 2001; 6: 6548-54.
154. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev 2003; 3: 721-32.
155. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997; 94: 8104-9.
156. Ryan HE, Lo J, Johnson RS. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J 1998; 17: 3005-15.
157. Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, Krissansen GW. Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther 2001; 8: 638-45.
158. Unruh A, Resse A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, et al. The hypoxia-inducible factor-1α is a negative factor for tumor therapy. Oncogene 2003; 22: 3213-20.
159. Chen J, Zhao S, Nakada K, Kuge Y, Tamaki N, Okada F, et al. Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol 2003; 162: 1283-91.
160. Kung AL, Warg S, Klco JM, Kaelin WG Jr, Livingston DM. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 2000; 6: 1335-40.
161. Yeo E-J, Chun y-S, Cho Y-S, Kim J, Lee J-C, Kim M-S, et al. YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003; 95: 516-25.
162. Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RN, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002; 62: 4316-24.
163. Brtko J, Thalhamer J. Renaissance of the biologically active vitamin A derivatives: established and novel directed therapies for cancer and the chemoprevention. Curr Pharm Design 2003; 9(25): 2067-77.
164. Hewitson KS, McNeill LA, Schofield CJ. Modulating the hypoxia-inducible factor signaling pathway: applications from cardiovascular disease to cancer. Curr Pharm Design 2004; 10(8): 821-33.
165. Mazure NM, Brahimi-Horn MC, Pouyssegur J. Protein kinases and the hypoxia-inducible factor-1, two switches in angiogenesis. Curr Pharm Design 2003; 9(7): 531-41.